Reports
Sale
Global Cardiovascular Drugs Market Size, Report: By Drug Class: Antihypertensive Drugs, Anticoagulants, Antiplatelet Agents, Antihyperlipidemic Drugs, Antiarrhythmic Drugs, Others; By Indications; By Route of Administration; By Drug Type; By End User; By Distribution Channel; Regional Analysis; Competitive Landscape; 2024-2032
Global Cardiovascular Drugs Market Outlook
The global cardiovascular drugs market size attained a value of USD 64.97 billion in 2023. The market is anticipated to grow at a CAGR of 2.66% during the forecast period of 2024-2032, driven by the rising prevalence of cardiovascular diseases across the globe. The global cardiovascular drugs market share is anticipated to achieve a value of USD 82.24 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
North America to Lead the Global Cardiovascular Drugs Market
North America dominates the global cardiovascular drugs industry, owing to the increased awareness about various heart diseases within the region. The United States represent the most important marketplace for cardiovascular drugs followed by Canada in North America. On the other hand, Asia Pacific is predicted to witness high growth rates in the coming years, thanks to many companies constructing their R&D facilities in the region. Less stringent wages and availability of skilled labour attracts manufacturing companies which is further boosting the growth in the Asia Pacific region.
Additionally, increasing awareness about heart related problems is supporting within the growth of cardiovascular drugs market within the region. China, India, and Japan are expected to be the fastest growing cardiovascular drugs markets thanks to rising cases of heart diseases and extensive pipeline drugs. Increasing ageing population and rising number of lifestyle diseases are also contributing to the growth of global cardiovascular drugs industry.
Cardio Vascular Drugs: Market Segmentation
Cardiovascular drugs refer to agents used for the treatment of diseases related to the cardiovascular system, which include blood clots, stroke, arteria coronaria disease, variation in vital sign, arrhythmias, high cholesterol, and coronary failure.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Cardiovascular drugs can be divided on the basis of drug type into:
- Antihypertensive
- Antihyperlipidemic
- Anticoagulants
- Antiarrhythmics
- Others
On the basis of disease indication, cardiovascular drugs can be divided into:
- Hypertension
- Hyperlipidemia
- Coronary Artery Disease
- Arrhythmia
- Others
Cardiovascular drugs can be segmented on the basis of distribution channel into:
- Hospital Pharmacies
- Retail Pharmacies
- Online
- Others
The regional markets for global cardiovascular drugs industry can be divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Rising Cases of Cardiovascular Diseases Boosting the Global Cardiovascular Drugs Industry
Cardiovascular drugs are extremely helpful in treating various heart related dysfunction. The rising prevalence of heart stroke and cardiovascular diseases is one among the key reasons for the expansion of the cardiovascular drugs market. Cardiovascular diseases have shown stable increase in prevalence worldwide, driven by numerous modern lifestyle changes. Factors like sedentary lifestyle, excess consumption of alcohol, stress, unhealthy eating habits, smoking are all factors liable for the rise within the number of cardiovascular disorders among the young population. A number of the opposite crucial drivers for global cardiovascular drugs industry growth is that the increased awareness regarding cardiovascular health and therefore the corresponding increase in product launches. The rising number of diabetic patients holds immense potential to the expansion of worldwide cardiovascular drugs industry.
Key Industry Players in the Global Cardiovascular Drugs Market
The report gives a detailed analysis of the following key players in the global cardiovascular drugs industry, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- F. Hoffmann-La Roche Ltd.
- Fresenius Kabi AG
- Bayer AG
- Sun Pharmaceutical Industries Ltd.
- Novartis AG
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Zydus Group
- Pfizer Inc.
- Lupin
- GSK Plc
- Glenmark Pharmaceuticals Inc.
- Capricor Therapeutics
- Zensun
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by Indications |
|
| Breakup by Route of Administration |
|
| Breakup by Drug Type |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Cardiovascular Drugs Market Overview
3.1 Global Cardiovascular Drugs Market Historical Value (2017-2023)
3.2 Global Cardiovascular Drugs Market Forecast Value (2024-2032)
4 Global Cardiovascular Drugs Market Landscape
4.1 Global Cardiovascular Drugs Company Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Cardiovascular Drugs Product Landscape
4.2.1 Analysis by Drug Class
4.2.2 Analysis by Indications
4.2.3 Analysis by Route of Administration
4.2.4 Analysis by End User
4.2.5 Analysis by Distribution Channel
5 Global Cardiovascular Drugs Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Cardiovascular Drugs Market Segmentation
6.1 Global Cardiovascular Drugs Market by Drug Class
6.1.1 Market Overview
6.1.2 Antihypertensive Drugs
6.1.3 Anticoagulants
6.1.4 Antiplatelet Agents
6.1.5 Antihyperlipidemic Drugs
6.1.6 Antiarrhythmic Drugs
6.1.7 Others
6.2 Global Cardiovascular Drugs Market by Indications
6.2.1 Market Overview
6.2.2 Hypertension
6.2.3 Coronary artery disease
6.2.4 Heart Failure
6.2.5 Arrhythmias
6.2.6 Dyslipidemia
6.2.7 Others
6.3 Global Cardiovascular Drugs Market by Route of Administration
6.3.1 Market Overview
6.3.2 Oral
6.3.3 Parenteral
6.3.4 Others
6.4 Global Cardiovascular Drugs Market by Drug Type
6.4.1 Market Overview
6.4.2 Branded
6.4.3 Generics
6.5 Global Cardiovascular Drugs Market by End User
6.5.1 Market Overview
6.5.2 Hospitals
6.5.3 Homecare
6.5.4 Specialty Clinics
6.5.5 Others
6.6 Global Cardiovascular Drugs Market by Distribution Channel
6.6.1 Market Overview
6.6.2 Hospitals Pharmacy
6.6.3 Online Pharmacy
6.6.4 Retail Pharmacy
6.6.5 Others
6.7 Global Cardiovascular Drugs Market by Region
6.7.1 Market Overview
6.7.2 North America
6.7.3 Europe
6.7.4 Asia Pacific
6.7.5 Latin America
6.7.6 Middle East and Africa
7 North America Cardiovascular Drugs Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Cardiovascular Drugs Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Cardiovascular Drugs Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Cardiovascular Drugs Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Cardiovascular Drugs Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 F. Hoffmann-La Roche Ltd.
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Fresenius Kabi AG
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Bayer AG
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Sun Pharmaceutical Industries Ltd.
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Novartis AG
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Mylan N.V.
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Teva Pharmaceutical Industries Ltd.
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Zydus Group
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Pfizer Inc.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Lupin
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 GSK Plc
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Glenmark Pharmaceuticals Inc.
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Capricor Therapeutics
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Zensun
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
18 Global Cardiovascular Drugs Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The global cardiovascular drugs market is projected to grow at a CAGR of 1.5% between 2024 and 2032.
The major drivers of the market include the sedentary lifestyle, excess consumption of alcohol, stress and smoking, increased awareness regarding cardiovascular health, unhealthy eating habits, increasing ageing population, and rising number of lifestyle diseases.
The rising prevalence of heart stroke and cardiovascular diseases and the rising number of diabetic patients are the key industry trends propelling the market's growth.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
Cardiovascular drugs can be divided on the basis of drug type into antihypertensive, antihyperlipidemic, anticoagulants, and antiarrhythmics, among others.
Based on disease indication, cardiovascular drugs can be divided into hypertension, hyperlipidemia, coronary artery disease, and arrhythmia, among others.
The distribution channels include hospital pharmacies, retail pharmacies, and online, among others.
The major players in the industry are Baxter International Inc., Pfizer Inc., Bayer AG, Johnson & Johnson Services, Inc., Novartis AG, and Boehringer Ingelheim International GmbH, among others.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$ 3499
$1999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5999
$2999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 7999
$3999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9999
$5999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER